t-butyl 2-bromo-7-carboxyxanthene-9-carboxylate | 202796-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: t-butyl 2-bromo-7-carboxyxanthene-9-carboxylate
• 英文别名: 7-bromo-9-t-butoxycarbonylxanthene-2-carboxylic acid；7-bromo-9-[(2-methylpropan-2-yl)oxycarbonyl]-9H-xanthene-2-carboxylic acid
• CAS: 202796-82-5
• 化学式: C₁₉H₁₇BrO₅
• 分子量: 405.245
• InChiKey: BZTNDNVJJLTKRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  483.0±45.0 °C(Predicted)
• 密度：
  1.484±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  t-butyl 2-bromo-7-carboxyxanthene-9-carboxylate 在 palladium on activated charcoal 氢气 作用下， 以 乙酸乙酯 、 叔丁醇 为溶剂， 反应 12.0h， 以100%的产率得到t-butyl 2-carboxyxanthene-9-carboxylate
  参考文献：
  名称：

  Structure–activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists

  摘要：

  The structure-activity relationships of xanthene carboxamide derivatives on the CCR1 receptor binding affinity and the functional antagonist activity were described. Previously, we reported a quaternarized xanthen-9-carboxamide I as a potent human CCR1 receptor antagonist that was derived from a xanthen-9-carboxamide lead 2a. Further derivatization of 2a focusing on installing an additional substituent into the xanthene ring resulted in the identification of 2b-1 with IC50 values of 1.8 nM and 13 nM in the binding assay using human CCRI receptors transfected CHO cells and in the functional assay using U937 cells expressing human CCRI receptors, respectively. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00559-x
• 作为产物：
  描述：

  2,7-dibromoxanthene-9-carboxylic acid 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 氯仿 为溶剂， 反应 14.5h， 生成 t-butyl 2-bromo-7-carboxyxanthene-9-carboxylate
  参考文献：
  名称：

  Structure–activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists

  摘要：

  The structure-activity relationships of xanthene carboxamide derivatives on the CCR1 receptor binding affinity and the functional antagonist activity were described. Previously, we reported a quaternarized xanthen-9-carboxamide I as a potent human CCR1 receptor antagonist that was derived from a xanthen-9-carboxamide lead 2a. Further derivatization of 2a focusing on installing an additional substituent into the xanthene ring resulted in the identification of 2b-1 with IC50 values of 1.8 nM and 13 nM in the binding assay using human CCRI receptors transfected CHO cells and in the functional assay using U937 cells expressing human CCRI receptors, respectively. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00559-x

文献信息

• Chemokine receptor antagonists
  申请人：Banyu Pharmaceutical, Co., Ltd.

  公开号：US06140338A1

  公开（公告）日：2000-10-31

  The present invention relates to a compound of the general formula: ##STR1## wherein each of R.sup.1 and R.sup.2 which may be the same or different, is e.g. a hydrogen atom, a halogen atom or a lower alkyl group, X is an oxygen atom, a sulfur atom or CH, Y is CH or a nitrogen atom, and A is e.g. a 1-substituted-4-piperidinyl group, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable anion-exchange product thereof or a hydrate thereof. The compounds of the present invention have chemokine receptor antagonism, and thus they are useful as treating agents for various diseases relating to chemokine, such as acute inflammatory diseases, chronic inflammatory diseases, acquired immune deficiency syndrome, cancer, ischemic reflow disorder and/or arteriosclerosis.

  本发明涉及一般式的化合物：##STR1##其中R.sup.1和R.sup.2中的每一个可以相同也可以不同，例如是氢原子、卤素原子或低碳基团，X是氧原子、硫原子或CH，Y是CH或氮原子，A是例如1-取代-4-哌啶基团，其药学上可接受的盐，其药学上可接受的阴离子交换产物或其水合物。本发明的化合物具有趋化因子受体拮抗作用，因此它们可用作治疗与趋化因子相关的各种疾病的药剂，如急性炎症性疾病、慢性炎症性疾病、获得性免疫缺陷综合症、癌症、缺血再灌注障碍和/或动脉粥样硬化。
• CHEMOKINE RECEPTOR ANTAGONISTS
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0916668A1

  公开（公告）日：1999-05-19

  The present invention relates to a compound of the general formula: wherein each of R1 and R2 which may be the same or different, is e.g. a hydrogen atom, a halogen atom or a lower alkyl group, X is an oxygen atom, a sulfur atom or CH, Y is CH or a nitrogen atom, and A is e.g. a 1-substituted-4-piperidinyl group, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable anion-exchange product thereof or a hydrate thereof. The compounds of the present invention have chemokine receptor antagonism, and thus they are useful as treating agents for various diseases relating to chemokine, such as acute inflammatory diseases, chronic inflammatory diseases, acquired immune deficiency syndrome, cancer, ischemic reflow disorder and/or arteriosclerosis.

  本发明涉及通式如下的化合物： 其中R1和R2可以相同或不同，每个R1和R2例如是氢原子、卤素原子或低级烷基，X是氧原子、硫原子或CH，Y是CH或氮原子，A例如是1-取代-4-哌啶基、其药学上可接受的盐、其药学上可接受的阴离子交换产物或其水合物。 本发明的化合物具有趋化因子受体拮抗作用，因此可作为治疗与趋化因子有关的各种疾病的药物，如急性炎症性疾病、慢性炎症性疾病、获得性免疫缺陷综合征、癌症、缺血性回流障碍和/或动脉硬化。
• US6140338A
  申请人：——

  公开号：US6140338A

  公开（公告）日：2000-10-31
• Structure–activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists
  作者：Akira Naya、Makoto Ishikawa、Kenji Matsuda、Kenji Ohwaki、Toshihiko Saeki、Kazuhito Noguchi、Norikazu Ohtake

  DOI：10.1016/s0968-0896(02)00559-x

  日期：2003.3

  The structure-activity relationships of xanthene carboxamide derivatives on the CCR1 receptor binding affinity and the functional antagonist activity were described. Previously, we reported a quaternarized xanthen-9-carboxamide I as a potent human CCR1 receptor antagonist that was derived from a xanthen-9-carboxamide lead 2a. Further derivatization of 2a focusing on installing an additional substituent into the xanthene ring resulted in the identification of 2b-1 with IC50 values of 1.8 nM and 13 nM in the binding assay using human CCRI receptors transfected CHO cells and in the functional assay using U937 cells expressing human CCRI receptors, respectively. (C) 2003 Elsevier Science Ltd. All rights reserved.